OnCore Login

Return to Trial Database

BRE09-146

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

Status

Study Completed

Cancer Type(s)

Breast

Study Contact

Publications

Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of BRE09-146
  • K Miller, Y Tong, DR Jones, T Walsh, MA Danso, CX Ma, P Silverman, MC King, SS Badve, SM Perkins
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer
  • S Dwadasi, Y Tong, T Walsh, MA Danso, CX Ma, PA Silverman, MC King, SM Perkins, SS Badve, K Miller
PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations
  • SR Malireddy, SM Perkins, SS Badve, GW Sledge, K Miller
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
  • M Kalra, Y Tong, DR Jones, T Walsh, MA Danso, CX Ma, P Silverman, M King, SS Badve, SM Perkins, KD Miller

Trial Locations

All sites in which the trial BRE09-146 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278